Sponsored by: Investment Center

Something new in your business?  Click here to submit your business press release

Chamber Corner | Main Street News | Job Hunt | Classifieds | Calendar | Illinois Lottery 

FDA approves once-a-day inhaler from Glaxo

[May 11, 2013]  WASHINGTON (AP) -- The Food and Drug Administration says it has approved a new once-a-day inhaler drug from GlaxoSmithKline for patients with chronic lung disease.

The agency cleared the Breo Ellipta inhaler for long-term use and to control flare-ups in patients with chronic obstructive pulmonary disorder, often called smoker's cough. The lung ailment can cause a number of breathing problems, including chronic bronchitis and emphysema.

Breo Ellipta delivers a combination of two drugs that reduce inflammation in the lungs and relax airways to ease breathing. The drug carries a warning that it is not approved for asthma.

Glaxo, a leader in respiratory medicine, already sells the asthma treatment Advair, its best-selling product with more than $4 billion in sales per year. The British drugmaker collaborated on the inhaler with South San Francisco-based Theravance.

[Associated Press]

Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.